Market capitalization | $239.03m |
Enterprise Value | $92.41m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.72 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-93.36m |
Free Cash Flow (TTM) Free Cash Flow | $-67.37m |
Cash position | $157.02m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a Lexeo Therapeutics forecast:
7 Analysts have issued a Lexeo Therapeutics forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.97 -1.97 |
-
|
|
EBITDA | -91 -91 |
-
|
EBIT (Operating Income) EBIT | -93 -93 |
-
|
Net Profit | -87 -87 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Head office | United States |
CEO | R. Townsend |
Employees | 58 |
Founded | 2017 |
Website | www.lexeotx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.